

PATENT

Attorney Docket No. 7372/72249

# IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Application of:

ASAKO et al.

Group Art Unit:

Not Yet Assigned

Application No.

010/004,115

Examiner:

Not Yet Assigned

Filed:

December 6, 2001

For:

PROCESS FOR PRODUCING OPTICALLY ACTIVE 4-HALO-3-HYDROXYBUTANOATE

RECEIVED

INFORMATION DISCLOSURE STATEMENT

JAN 2 3 2003

Commissioner for Patents Washington, D.C. 20231

TECH CENTER 1600/2900

Pursuant to 37 CFR 1.97 and 1.98, the references listed on the enclosed Form PTO-1449 and/or Substitute Form PTO-1449 ("Form 1449") are submitted for consideration by the Examiner in the examination of the above-identified patent application.

The full consideration of the references in their entirety by the Examiner is respectfully requested and encouraged. Also, it is respectfully requested that the references be entered into the record of the present application and that the Examiner place his or her initials in the appropriate area on the enclosed Form, similar to Form1449, thereby indicating the Examiner's consideration of each of the references.

The submission of the references listed on the Form is for the purpose of providing a complete record and is not a concession that the references listed thereon are prior art to the invention claimed in the patent application. The right is expressly reserved to establish an invention date earlier than the above-identified filing date in order to remove any reference submitted herewith as prior art should it be deemed appropriate to do so.

Further, the submission of the references is not to be taken as a concession that any reference represents art that is relevant or analogous to the claimed invention. Accordingly, the right to argue that any reference is not properly within the scope of prior art relevant to an examination of the claims in the above-identified application is also expressly reserved.

The Information Disclosure Statement is being filed:

(X) within any one of the following time periods: (a) within three months of the filing date of a national application other than a continued prosecution application under 37 CFR 1.53(d); (b) within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 of an international application; (c) before the mailing date

In re Appln. of ASKAO et al. Application No. 10/004,115

of a first Office Action on the merits; or (d) before the mailing of a first Office Action after the filing of a request for continued examination under 37 CFR 1.114.

It will be specifically noted that the information was first cited by a foreign patent office only one month ago on December 23, 2002. (In the rush before the end of year holidays, the date stamp from a foreign associate attorney was inadvertently set to December 20, 2002, which is physically impossible because the foreign patent office communication did not issue until three days later, December 23, 2002.)

- () **after** (a), (b), (c) or (d) above, but before the mailing date of a final action under 37 CFR 1.113, a Notice of Allowance under 37 CFR 1.311, or an action that otherwise closes prosecution in the application, and includes *one* of:
  - () the Statement under 37 CFR 1.97(e) (see "Statement under 37 CFR 1.97(e)" below).

or

- () the fee of \$180 set forth in 37 CFR 1.17(p) (see "Fees" below).
- after the mailing date of a final action under 37 CFR 1.113 or a Notice of Allowance under 37 CFR 1.311, or an action that otherwise closes prosecution in the application, and on or before payment of the issue fee, and includes the Statement under 37 CFR 1.97(e) (see "Statement under 37 CFR 1.97(e)" below), and the fee of \$180 as set forth in 37 CFR 1.17(p) (see "Fees" below).
- () **after** the mailing date of a Notice of Allowance under 37 CFR 1.311, and on or before payment of the issue fee, and **within** thirty days of receiving each item of information contained in the Information Disclosure Statement, and includes the Statement under 37 CFR 1.704(d) (see "Statement under 37 CFR 1.704(d)" below), and the fee of \$180 as set forth in 37 CFR 1.17(p) (see "Fees" below).

  NOTE: This is for original applications except applications for a design patent, filed on or after May 29, 2000, wherein a paper containing only an Information Disclosure Statement in compliance with 37 CFR 1.97 and 1.98 is being filed.

## **Copies of the References**

- (X) Copies of the references listed on the enclosed Form are enclosed herewith.
- (X) A copy of the foreign search report is enclosed herewith.
- () The references listed on the enclosed Form were previously identified in the parent application(s) of the present application, and copies of the references were furnished at that time. Accordingly, additional copies of the references are not submitted herewith, so as not to burden the file with duplicate copies of references. The

In re Appln. of ASKAO et al. Application No. 10/004,115

Examiner is respectfully requested to carefully review the references in accordance with the requirements set out in the Manual of Patent Examining Procedure. In accordance with 37 CFR 1.98(d), the details of the parent application(s) relied upon for an earlier filing date under 35 USC 120 in which copies of the references were previously furnished are set out below:

\* \* \*

U.S. APPLI	Status (check one)			
U.S. APPLICATIONS	U.S. FILING DATE	PATENTED	PENDING	ABANDONE D
1.				
2.				
3.				

## Statement under 37 CFR 1.97(e)

- () The **undersigned** hereby states that each item of information contained in the Information Disclosure Statement was first cited in any communication from a foreign patent office in a counterpart foreign patent application not more than three months prior to the filing of the Information Disclosure Statement.
- () The **undersigned** hereby states that no item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign patent application, and, to the knowledge of the undersigned after making reasonable inquiry, no item of information contained in the Information Disclosure Statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the Information Disclosure Statement.

### Statement under 37 CFR 1.704(d)

(X) The **undersigned** hereby states that each item of information contained in the Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart application and that this communication was not received by any individual designated in 37 CFR 1.56(c) more than thirty days prior to the filing of the Information Disclosure Statement.

In re Appln. of ASKAO et al. Application No. 10/004,115

#### Fees

- (X) **No fee** is owed by the applicant(s).
- ( ) The **IDS Fee of \$180** under 37 CFR 1.17(p) is enclosed herewith.

## **Method of Payment of Fees**

- () Attached is a check in the amount of \$
- () Charge Deposit Account No. 06-1135 regarding our order number 7372/72249 in the amount of \$ . (A duplicate copy of this communication is enclosed for that purpose.)

# Authorization to Charge Additional Fees

(X) If any additional fees are owed in connection with this communication, please charge Deposit Account No. 06-1135 regarding our order number 7372/72249. (A duplicate copy of this communication is enclosed for that purpose.)

## **Instructions as to Overpayment**

- (X) Credit Account No. 06-1135.
- () Refund

Respectfully submitted,

FITCH, EVEN, TABIN & FLANNERY

Kendrew H. Colton

Registration No. 30,368

Telephone: (202) 419-7000 Facsimile: (202) 419-7007

#### **NEW ADDRESS:**

1801 K Street, N.W.

Suite 400L

Washington, D.C. 20006-1201 Telephone: (202) 419-7000

Facsimile: (202) 419-7007

JAN 2 2 2003 By		
PTO/SB/08A TRADES Substitute for Form PTO-1449	Application	10/004,115
	Filing Date	December 6, 2001
INFORMATION DISCLOSURE	First Named	ASAKO et al.
STATEMENT BY	Art Unit	Not Yet Assigned
APPLICANT	Examiner Name	Not Yet Assigned
page 1 of 2	Attorney Docket	7372/72249

		U.	S. PATENT D	OCUMENTS	
Examine r	Cit e No.	Document Number	Publication Date	Name of Patentee or Applicant of Cited	Pages, Columns, Lines Where Relevant Passages or Relevant Figures
Initials*	<u> </u>	Number-Kind Code <sup>2</sup>	MM-DD-YYYY	Document	Appear
		US-4,978,768	12/18/1990	von der Crone	
		US-			RECEIVED
·		US-			JAN 2 3 2003
		US-			
		US-			TECH CENTER 1600/
		US-			
		US-	i		
		US-			
		US-			
		US-			

		FOREIGN	N PATENT D	OCUMENTS		Γ
Examin	Cit e	Foreign Patent Document	Publication Date	Name of Patentee or	Pages, Columns, Lines Where Relevant Passages	
Δr	Ņο.	Country Code <sup>3</sup> -Number <sup>4</sup> -Kind Code <sup>5</sup>	MM-DD-YYY Y	Applicant of Cited Document	or Relevant Figures Appear	Тe
		PCT WO 00/71503 A1	11/30/2000	Hollingsworth et		
		EP 1201647 A2	05/2/2000	Wakita et al.		
ļ						
						Ш
	L					

Examiner	Date	
C:	Date	
Signature	Considered	

<sup>\*</sup>EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique estation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

JAN 5 5 5003

PTO/SB/08A	Application	10/004,115
Substitute for Form PTO-1449	Filing Date	December 6, 2001
INFORMATION	First Named	ASAKO et al.
DISCLOSURE STATEMENT BY APPLICANT	Art Unit	Not Yet Assigned
	Examiner Name	Not Yet Assigned
Sheet 2 of 2	Attorney Docket	7372/72249

		OTHER PRIOR ART - NON PATENT LITERATURE DOCUMENTS	
		THE THE TOTAL THE TOTAL TOTAL TOTAL DOCUMENTS	т—
Examine r Initials*	Cit e No.	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		Itoh et al., Purification and Characterization of Phenylacetaldehyde Reductase and a Styrene-Assimilating Corynebacterium Strain, ST-10, Applied and Environmental Microbiology, pp 3783-3788 (Oct. 1997)	
		Itoh et al., Chiral alcohol production by NADH-dependent phenylacetaldehyde reductase coupled with in situ regeneration of NADH, Eur. J. Biochem., 269:2394-2402 (2002)	
		Itoh et al., Cloning, sequence analysis, and expression in Escherichia coli of the gene encoding phenylacetaldehyde reductase from styrene-assimilating Corynebacterium sp. strain ST-10, Appl. Microbiol. Biotechnol. 52:386-392 (1999)	
		Itho et al., Production of chiral alcohols by enantioselective reduction with NADH-dependent phenylacetaldehyde reductase from Corynebacterium strain, ST-10, Journal Molecular Catalysis B:Enzymatic 6:41-50 (1999)	
		Troostwijk et al., Method for the Synthesis of 4-substituted Acetoacetates, Journal of the Chemical Society Chem. Comm. no.23, pages 932-933 (Dec. 7, 1977)	
		-11/ED	
		RECEIVED	$\vdash$
		RECEIVED  JAN 2 3 2003	
		TECH CENTER 1600	590
	ļ		

E E	The same of the sa		
Examiner Signature		Date Considered	

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.
Applicant's unique citation designation number (optional). Applicant is to place a check mark here if English language

Translation is attached.

**RECEIVED** 

JAN 2 3 7003

TECH CENTER 1600/2900